Norgine launches Shield’s Feraccru in the UK
Norgine has launched Feraccru across the UK to treat patients with iron deficiency anaemia, having picked up rights to sell the drug from Shield Therapeutics earlier this year.
Read More
Tag: Shield Therapeutics
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
